Ariad Pharmaceuticals Inc
ARIA
ARIA was delisted on the 15th of February, 2017.
177 hedge funds and large institutions have $1.16B invested in Ariad Pharmaceuticals Inc in 2015 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 49 increasing their positions, 71 reducing their positions, and 34 closing their positions.
4% less call options, than puts
Call options by funds: $24.2M | Put options by funds: $25.1M
6% less capital invested
Capital invested by funds: $1.23B → $1.16B (-$70.6M)
8% less funds holding
Funds holding: 193 → 177 (-16)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
31% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 71
47% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.13M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$6.8M |
| 3 |
Two Sigma Investments
New York
|
+$6.23M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$11.1M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$10.9M |
| 3 |
Millennium Management
New York
|
-$8.59M |
| 4 |
AC
Ascend Capital
Orinda,
California
|
-$8.24M |
| 5 |
PC
PointState Capital
New York
|
-$7.96M |
ARIA Hedge Fund Activity: Q2 2015 in Review
177 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q2 2015, worth a combined $1.16B — down 5.7% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ARIA and 18 opened new positions — a net loss of 16 holders — while 71 trimmed existing stakes and 49 added.
The largest buyer was Balyasny Asset Management, adding an estimated $7.13M. The largest seller was Camber Capital Management, cutting an estimated $11.1M.
- 177 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q2 2015, down from 193 in Q1 2015.
- Funds reported $1.16B of Ariad Pharmaceuticals Inc stock for Q2 2015, down 5.7% quarter-over-quarter.
- 18 funds opened new Ariad Pharmaceuticals Inc positions in Q2 2015 and 34 closed out, a net change of -16 holders.
- The largest Ariad Pharmaceuticals Inc buyer in Q2 2015 was Balyasny Asset Management, an estimated $7.13M added.
- The largest Ariad Pharmaceuticals Inc seller in Q2 2015 was Camber Capital Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2015.